Merck & Co.
AWARDS
NEWS
Scot Ebbinghaus, Vice President and Therapeutic Area Head, Oncology Clinical Research, Merck Research Laboratories, took time out ahead of the meeting to discuss three of the company’s clinical trials being presented and the implications for oncology patients and Merck.
As summer winds its way to an end, biopharmaceutical companies continue to conduct clinical trials and release news related to them. Here’s a look at last week’s clinical trial headlines.
For the second time in a Phase III trial, Lynparza met its endpoints as a potential first-line treatment for ovarian cancer.
Merck’s Keytruda has become one of the best-selling drugs in the world. Last year, it generated more than $7 billion in revenue for Merck and that is only predicted to grow, particularly as the drug wins approval for new indications.
Privately-held Oncologie will conduct a Phase II study of the combination study for patients who have failed at least one line of treatment for gastric or gastroesophageal cancer.
Last week was a particularly busy week for biopharma companies to release information about ongoing clinical trials. Here’s a look.
JOBS
IN THE PRESS